



MEMBER SPOTLIGHT

Eli Lilly & Company

Jan 2025





Indianapolis

All the information mentioned here is publicly available, references can be provided upon request.

Strong Global Performance for Lilly

Nearly 150 years
of improving lives worldwide

Over 46,000
employees globally

\$9.3 billion
Invested in R&D in 2023
(27.3% of sales)

2024 revenue is expected to
be approximately

\$45 billion

Introduction

For nearly 150 years, Lilly has been at the forefront of pharmaceutical research and development, driven by a deep commitment to improving patient outcomes. This dedication is evident in their robust pipeline, the richest in the industry, and their consistent delivery of breakthrough therapies across key therapeutic areas. Today the company's medicines help around 51 million people across the globe:

Diabetes, Obesity, and Cardiometabolic Diseases

With a portfolio of innovative therapies, Lilly is reshaping the treatment landscape for type 2 diabetes and obesity.

Immunology

Lilly is committed to providing solutions for patients with immune-system disorders. Their portfolio addresses conditions such as psoriasis, arthritis, and ulcerative colitis.

Neuroscience

Lilly is at the forefront of developing therapies for severe neurological conditions. They are also pioneering research in Alzheimer's disease with a potential breakthrough therapy currently under regulatory review.

Oncology

Lilly is committed to developing innovative cancer therapies to improve patient outcomes. Their portfolio addresses various cancers, and they are actively advancing their pipeline with promising treatments for breast cancer.

Future Breakthrough Medicines

Lilly is growing their global external partnerships to prepare for future breakthrough medicines

- Speeding their latest innovations to patients who are waiting by reimagining processes, building new capabilities and accelerating the delivery of medicines
- Advancing health equity efforts through new charitable programs across the globe
- 2024: announced two major R&D investments
 - Lilly Seaport Innovation Center
 - Lilly Medicine Foundry

Lilly Invests in the Future

Helping around 51 million
people around the world

+\$23 billion
Investments in manufacturing since 2020

Clinical research conducted in more than
55 countries

23.7%
Of total workforce work in R&D

Accelerating drug development reducing
the average timeline
from 11 to 6 years

19 new medicines
have been launched since 2014

U.S.-U.A.E. Collaborations

Notable Collaborations in 2024

In March 2024, the Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, announced a groundbreaking collaboration with Lilly and the World Obesity Federation (WOF). This multisectoral collaboration aims to transform the approach to obesity prevention and management. It aligns with Abu Dhabi's mission to improve health outcomes and promote longevity across the Emirate. The initiative further reinforces Abu Dhabi's position as a leading hub for healthcare innovation, driving advanced prevention strategies.



The Mission

The collaboration is a testament to a strong U.S.-U.A.E. focus, emphasizing the critical role that Lilly will play in advancing obesity care in the U.A.E. By leveraging the combined knowledge and experience of these organizations, the initiative is set to lead the charge in developing ground-breaking healthcare solutions. It aims to provide healthcare professionals with robust strategies for effective management and significantly elevate public consciousness about the importance of treating obesity as a chronic disease.

Executive Insights with Ilya Yuffa, Executive Vice President & President Lilly International



CNBC Interview

Watch CNBC Arabia's interview with Ilya Yuffa, where he highlights Lilly's commitment to R&D and groundbreaking innovations and discusses the company's strategic growth in the region.

[Watch here](#)

Dubai Eye 103.8

Ilya Yuffa, Executive Vice President and President Lilly International, discusses the significance of the U.A.E. market for the company. [Listen here](#)



Irina Zaporozhets

Forbes interviewed Irina Zaporozhets, Lilly's President and General Manager for the Middle East, in its September 2024 issue profiling the top 100 healthcare leaders in the Middle East. In this interview, Irina highlights Lilly's commitment to innovation and improving patient care within this region.

[Read more](#)

Contact

Andrea Prerad

Communications Strategy Lead Middle East & Turkiye Area

E: Andrea.Prerad@Lilly.com

T: +971 56 687 4443

For adverse events and safety reporting, please send an email: PV-MEA@lilly.com. For product complaints, please send an email: lbmail_pc_mena@lilly.com

Address

Al Hayyan Building, Building No.25, 6th Floor,
Al Riyadh Street, Dubai Healthcare City, Dubai, U.A.E.



U.S.-U.A.E. Business Council
usuaebusiness.org

@USUAEBizCouncil